Key Laboratory of Smart Drug Delivery, Ministry of Education (Fudan University), Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, PR China.
Department of Hematology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, PR China.
Acta Biomater. 2020 Apr 1;106:301-313. doi: 10.1016/j.actbio.2020.02.013. Epub 2020 Feb 17.
Corosolic acid (CA), a natural pentacyclic triterpenoid, exhibits antitumor and synergistic therapy effect with chemotherapeutic drugs mainly through inhibiting STAT3 activation. In this study, it is found that CA possesses cholesterol-like properties in liposome by regulating membrane phase behavior to form stable cholesterol-free CA liposomes (CALP). Compared with traditional cholesterol liposomes (CHOLP), CALP exhibit stronger membrane fusion and higher cellular uptake, and other functions including inhibition of STAT3 activation and suppression of the recruitment of macrophages to tumor microenvironment. Therefore, CALP is used as a functional carrier, and doxorubicin-loaded CALP (DOX/CALP) based on PEGylated liposomal doxorubicin (DOXIL) are prepared by replacing its cholesterol with CA. The physicochemical properties and biological activities are compared with those of doxorubicin-loaded cholesterol liposomes (DOX/LP). Both DOX/CALP and DOX/LP possess approximately similar physical properties and exhibit high stability and low drug leakage as shown by the published data of DOXIL. Nevertheless, it is noteworthy that DOX/CALP displays higher in vitro cellular uptake and tumor spheroid permeation along with stronger cytotoxicity against tumor cells than DOX/LP. Despite DOX/CALP has the same PK parameters, normal tissue biodistribution, and safety profile as DOX/LP, the results of an in vivo study in 4T1-bearing mice indicate that the DOX/CALP treatment group exhibit higher tumor accumulation, more significant tumor growth inhibition, and longer life span than the DOX/LP group. Overall, DOX/CALP is a representative example of CA-doped liposomes, suggesting that CALP as a functional drug carrier for solving low efficacy of present liposomal drugs might have promising application potential. STATEMENT OF SIGNIFICANCE: An original drug delivery nanocarrier, corosolic acid liposome (CALP), was developed in this study. It was found that CA possesses cholesterol-like function to regulate phospholipid membrane phase behavior. By replacing the cholesterol with CA, the liposomes were converted into high cellular uptake carriers, possessing anti-inflammatory activity and synergism with chemotherapeutic drugs. The variability of CALP formulations enabled to deliver therapeutic agents. The use of CALP to deliver doxorubicin not only significantly enhanced the therapeutic efficacy compared with the classic PEGylated liposomal doxorubicin, but also maintained the improved safety. Because CALP can be obtained by conventional liposome preparation methods, its use as functional drug carriers for solving low efficacy of present liposomal drugs would have promising application potential.
没食子酸(CA)是一种天然五环三萜,主要通过抑制 STAT3 激活,与化疗药物表现出抗肿瘤和协同治疗作用。在这项研究中,发现 CA 通过调节膜相行为具有类胆固醇特性,从而形成稳定的无胆固醇 CA 脂质体(CALP)。与传统的胆固醇脂质体(CHOLP)相比,CALP 表现出更强的膜融合和更高的细胞摄取能力,以及其他功能,包括抑制 STAT3 激活和抑制巨噬细胞募集到肿瘤微环境。因此,CALP 被用作功能载体,并通过用 CA 取代其胆固醇来制备基于聚乙二醇化阿霉素脂质体(DOXIL)的载多柔比星 CALP(DOX/CALP)。通过与载多柔比星胆固醇脂质体(DOX/LP)的比较,研究了其理化性质和生物学活性。如 DOXIL 公布的数据所示,DOX/CALP 和 DOX/LP 均具有相似的物理性质,表现出高稳定性和低药物泄漏。然而,值得注意的是,与 DOX/LP 相比,DOX/CALP 具有更高的体外细胞摄取和肿瘤球体渗透能力以及更强的抗肿瘤细胞毒性。尽管 DOX/CALP 具有与 DOX/LP 相同的 PK 参数、正常组织分布和安全性特征,但在 4T1 荷瘤小鼠的体内研究结果表明,DOX/CALP 治疗组的肿瘤积累更高,肿瘤生长抑制更显著,生存期更长。总之,DOX/CALP 是 CA 掺杂脂质体的一个代表性例子,表明 CALP 作为解决现有脂质体药物疗效低的功能性药物载体可能具有广阔的应用前景。
在这项研究中,开发了一种新型药物递送纳米载体,即没食子酸脂质体(CALP)。研究发现 CA 具有类胆固醇功能,可以调节磷脂膜相行为。通过用 CA 取代胆固醇,脂质体转化为高细胞摄取载体,具有抗炎活性,并与化疗药物具有协同作用。CALP 制剂的可变性使能够递送治疗剂。使用 DOX/CALP 不仅与经典的聚乙二醇化阿霉素脂质体相比显著增强了治疗效果,而且保持了改善的安全性。由于 CALP 可以通过常规脂质体制备方法获得,因此将其用作解决现有脂质体药物疗效低的功能性药物载体具有广阔的应用前景。